Evidence map›Paper›PMID 38561092›Full record

ReviewBiochemical pharmacology2024

The role of oxidative stress in blood-brain barrier disruption during ischemic stroke: Antioxidants in clinical trials.

Jeffrey J Lochhead, Patrick T Ronaldson, Thomas P Davis

Open access · greenAbstract readReview
In one paragraph

Review in Biochemical pharmacology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
35citing papers in PubMed, 1 pooled it
9.4field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

35 citing papers in PubMed, 1 synthesis or guideline pooled it, 38 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Review
  4. Review
  5. Article
  6. Article
  7. Review
  8. Review
  9. Article
  10. Article
  11. Article
  12. Review
  13. Review
  14. Article
  15. Article
  16. Review
  17. Review
  18. Review
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Jeffrey J LochheadDepartment of Pharmacology, University of Arizona College of Medicine, Tucson, AZ 85724, USA. Electronic address: lochhead@arizona.edu.
Patrick T RonaldsonDepartment of Pharmacology, University of Arizona College of Medicine, Tucson, AZ 85724, USA.
Thomas P DavisDepartment of Pharmacology, University of Arizona College of Medicine, Tucson, AZ 85724, USA.
University of Arizona · US

Funding

Targeting Blood-Brain Barrier Transporters to Treat Ischemic StrokeR01NS084941 · NINDS · UNIVERSITY OF ARIZONA · PI RONALDSON, PATRICK THOMAS · 2014 to 2024
$4.4M
Increased CNS Opioid Exposure by an Acetaminophen-Induced Blood-Brain Barrier MechanismR01DA051812 · NIDA · UNIVERSITY OF ARIZONA · PI DAVIS, THOMAS PAUL, RONALDSON, PATRICK THOMAS · 2020 to 2024
$2.8M
NIDA NIH HHS R01 DA051812NINDS NIH HHS R01 NS084941
6 · The paper itself

Abstract

Ischemic stroke is one of the leading causes of death and disability. Occlusion and reperfusion of cerebral blood vessels (i.e., ischemia/reperfusion (I/R) injury) generates reactive oxygen species (ROS) that contribute to brain cell death and dysfunction of the blood-brain barrier (BBB) via oxidative stress. BBB disruption influences the pathogenesis of ischemic stroke by contributing to cerebral edema, hemorrhagic transformation, and extravasation of circulating neurotoxic proteins. An improved understanding of mechanisms for ROS-associated alterations in BBB function during ischemia/reperfusion (I/R) injury can lead to improved treatment paradigms for ischemic stroke. Unfortunately, progress in developing ROS targeted therapeutics that are effective for stroke treatment has been slow. Here, we review how ROS are produced in response to I/R injury, their effects on BBB integrity (i.e., tight junction protein complexes, transporters), and the utilization of antioxidant treatments in ischemic stroke clinical trials. Overall, knowledge in this area provides a strong translational framework for discovery of novel drugs for stroke and/or improved strategies to mitigate I/R injury in stroke patients.

Indexed as

AntioxidantsBlood-Brain BarrierClinical Trials as TopicIschemic StrokeOxidative StressAnimalsHumansReactive Oxygen SpeciesReperfusion InjuryAntioxidantsReactive Oxygen SpeciesAntioxidantBlood-brain barrierDrug deliveryReactive oxygen speciesTight junctionsTransporters

Identifiers

PMID38561092
PMCPMC11410550
OpenAlexW4393340378

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.